Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16544907 | 0.87 | RORC (0.59) | EPHX2RORCMEN1NPC1MAPT | |
| SCHEMBL12437084 | 0.85 | PDE4D (0.58) | EPHX2MAPTKMT2A | |
| SCHEMBL8505957 | 0.84 | PDE4D (0.55) | RORC | |
| SCHEMBL8503889 | 0.83 | PDE4D (0.54) | RORC | |
| SCHEMBL9903720 | 0.82 | HRH1 (0.53) | EPHX2RORCHRH1CCR3MEN1 | |
| SCHEMBL3109672 | 0.81 | RORC (0.50) | EPHX2RORCMEN1NPC1MAPT | |
| SCHEMBL2215999 | 0.81 | UTS2R (0.50) | RORCMEN1NPC1MAPTRAB9A | |
| SCHEMBL3283342 | 0.81 | MAPT (0.45) | EPHX2HRH1CCR3MEN1MAPT | |
| SCHEMBL23365170 | 0.80 | HRH1 (0.48) | EPHX2RORCSCDHRH1CCR3 | |
| SCHEMBL18152362 | 0.80 | HRH3 (0.48) | EPHX2ALDH1A1UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| EP-1991233-A4 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| EP-1991233-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | Avalon Pharmaceuticals (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007098086-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | EPHX2 1406/4885RORC 1725/4885SCD 4250/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | EPHX2 1406/4885RORC 1725/4885SCD 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.